Haematopoietic stem cell gene therapy (Novartis/SyStemix)

N/A

Report date: 2024/08/30 17:11:29

Base Information

Drug NameHaematopoietic stem cell gene therapy (Novartis/SyStemix)
Drug Alias NameHSC anti-HIV therapyCD34 gene therapyHSC gene therapyCD34 anti-HIV therapyHaematopoietic stem cell anti-HIV gene therapy +[7] 
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Gene therapy
Mechanisms of ActionHIV integrase inhibitors
TargetsHIV integrase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma AgDuke-Nus
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDuke-NusNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A